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Non-small Cell Lung Cancer
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Peter C. Kohler, MD,§ Eric T. Lubiner, DO,‡ James D. Peyton, MD,† David M. Waterhouse, MD,
Howard A. Burris III, MD,*† and F. Anthony Greco, MD*†
Purpose: To assess time to progression (TTP) in elderly patients
with previously untreated nonsquamous non-small cell lung cancer
treated with pemetrexed/gemcitabine/bevacizumab or pemetrexed/
carboplatin/bevacizumab.
Methods: Eligible patients were aged 70 years or older with newly
diagnosed stage IIIB/IV nonsquamous non-small cell lung cancer;
Eastern Cooperative Oncology Group performance status 0 to 1; ade-
quate organ function; and no active central nervous system metastasis.
Patients were randomized 1:1 to cohort A (pemetrexed 500 mg/m2 IV,
gemcitabine 1500 mg/m2 IV, and bevacizumab 10 mg/kg IV; days 1
and 15 of 28-day cycles) or cohort B (pemetrexed 500 mg/m2 IV,
carboplatin area under the concentration-time curve 5 IV, and bevaci-
zumab 15 mg/kg IV; day 1 of 21-day cycles). After six cycles, stable/
responding patients continued bevacizumab until disease progression.
Results: Between March 2007 and December 2009, 110 patients
(median age, 76 years; 88% stage IV) were treated for medians of
2.5 cycles (cohort A) and 6 cycles (cohort B). Overall response rate
was 35% in both cohorts, with stable disease rates of 33% (A) and
45% (B). TTP by cohort was 4.7 and 10.2 months with median OS
7.5 and 14.8 months, respectively. Severe toxicities included the
following: neutropenia (A, 51% and B, 45%), fatigue (A, 36% and
B, 18%), anemia (A, 22% and B, 7%), infection (A, 25% and B,
7%), thrombocytopenia (A, 11% and B, 31%), and thromboembo-
lism (A, 7% and B, 7%). Three potential treatment-related deaths
occurred in cohort A (sepsis, thrombocytopenia, and myocardial
infarction) and two in B (sepsis and pulmonary hemorrhage).
Conclusions: Treatment with pemetrexed/carboplatin/bevacizumab
was associated with improved TTP and OS in this elderly population
and should be further evaluated. Treatment-related toxicities were
expected and usually manageable, although deaths occurred with
both regimens.
Key Words: Elderly, Pemetrexed, Bevacizumab, Non-small cell
lung cancer.
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Approximately 50% of patients diagnosed with non-smallcell lung cancer (NSCLC) are aged at least 70 years.1,2
Nevertheless, elderly patients are consistently underrepresented
in lung cancer clinical trials.3–6 Many older patients are not
eligible for trials because of comorbidities, concomitant medi-
cations, or poor performance status; and others may never be
offered opportunities for trial participation because of physician
concerns about toxicity.1,7 Consequently, the safety and potential
benefits of newer therapies have been understudied in a large
subset of patients with advanced lung cancer.8
Two recently approved therapies in NSCLC treatment
are pemetrexed and bevacizumab. Pemetrexed is a novel
multitargeted antifolate with proven efficacy and safety in
prospective randomized trials with platinum therapy in the
first-line nonsquamous NSCLC treatment setting9–11 and as a
single agent in maintenance and second-line settings.12,13
Pemetrexed has also been studied in a biweekly schedule with
gemcitabine in phase II trials at our center and by others and
has been shown to be well tolerated and associated with
overall response rates (ORRs) of approximately 20%.14–16
Bevacizumab is a monoclonal antibody to vascular endo-
thelial growth factor, which was shown to improve survival
when combined with carboplatin and paclitaxel in the first-line
treatment setting in patients with advanced nonsquamous
NSCLC.17 Eight-hundred seventy-five patients were enrolled in
this randomized phase III trial, and 224 (26%) of these patients
were aged at least 70 years. Nevertheless, in an unplanned
retrospective analysis of the elderly cohort,18 bevacizumab was
associated with possible harm and no survival benefit.
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We sought to prospectively assess the roles of two
modern chemotherapy regimens in elderly patients with
NSCLC. The favorable therapeutic index of pemetrexed in
patients with nonsquamous NSCLC made it a promising
platform therapy to combine with bevacizumab in these
patients. In this randomized phase II trial, we concurrently
evaluated two pemetrexed/bevacizumab regimens, one with
biweekly gemcitabine and a second with carboplatin, as
first-line regimens in elderly patients with advanced disease.
PATIENTS AND METHODS
This randomized, open-label, multicenter, phase II
study was initiated in March 2007 and completed enrollment
in December 2009. It was performed at selected sites in the
Sarah Cannon Research Institute Oncology Research Consor-
tium, a community-based clinical trial organization (Appen-
dix). This study was approved by the institutional review
boards of all participating sites before patient enrollment.
Eligibility
Patients aged 70 years or older with histologically
confirmed nonsquamous NSCLC were enrolled. Patients had
measurable disease by radiologic evaluation per RECIST
(version 1.0).19 Patients had unresectable stage III or IV
disease; had not received prior systemic therapy for advanced
disease (including erlotinib or gefitinib); had adequate organ
function (as defined by an absolute neutrophil count 1500/l;
platelets100,000/l; hemoglobin8 g/dl; serum creatinine of
1.5 mg/dl or creatinine clearance 50 ml/min; urine protein/
creatinine ratio of 1.0 or urine dipstick 2 for protein;
bilirubin 1.5 the upper limit of normal); and had an Eastern
Cooperative Oncology Group performance status of 0 or 1.
Exclusion criteria included the following: any hemoptysis
within 4 weeks before enrollment; untreated central nervous
system (CNS) metastases (patients with CNS metastases treated
with radiation or surgery were eligible if there was no evidence
of CNS disease progression after treatment); or significant car-
diovascular disease including unstable angina, myocardial in-
farction, or stroke within 6 months of enrollment or uncontrolled
hypertension (defined as systolic blood pressure 150 mm Hg
and/or diastolic blood pressure100 mm Hg despite antihyper-
tensive therapy). Therapeutic anticoagulation was not allowed,
however, patients could receive prophylactic anticoagulation
(e.g., port prophylaxis). All patients provided written informed
consent before study entry.
Pretreatment Evaluation
Patients underwent a medical history and physical exam-
ination before starting treatment. Complete blood counts and
comprehensive metabolic profiles were also assessed. Evalua-
tions for proteinuria, hypertension, and cardiac function by
electrocardiogram were performed. Baseline tumor measure-
ments were established by computed tomography (CT) of the
chest, abdomen, and pelvis, position emission tomography, and
CT or magnetic resonance imaging of the brain.
Treatment
Patients were randomized 1:1 to cohorts A or B. Pa-
tients randomized to cohort A received bevacizumab 10
mg/kg, pemetrexed 500 mg/m2, and gemcitabine 1500 mg/m2
intravenously on days 1 and 15 of each 28-day cycle. Patients
randomized to cohort B received bevacizumab 15 mg/kg,
pemetrexed 500 mg/m2, and carboplatin at a dose calculated
to produce an area under the concentration-time curve (AUC)
of 5 mg/ml/min intravenously on day 1 of each 21-day cycle.
Patients were restaged with CT scans every two cycles
(8 weeks) in cohort A or every three cycles (9 weeks) in cohort
B. Patients received a maximum of six cycles of chemotherapy
followed by maintenance bevacizumab if there was no evidence
of progressive disease (PD) or unacceptable toxicity.
Patients received folic acid 350 to 1000 g orally daily
and intramuscular injections of 1000 g vitamin B12 before
starting therapy and administered continuously (B12 every 9
weeks) until 3 weeks after the last dose of pemetrexed.
Routine antiemetics and dexamethasone were administered as
premedication in each cohort. Leucovorin could be used as a
rescue agent for cytopenias if necessary.
Eli Lilly (Indianapolis, IN) supplied the pemetrexed
and gemcitabine for the study, and Genentech (San Francisco,
CA) supplied the bevacizumab. Carboplatin was obtained
from commercial supplies.
Dose Modifications
Toxicity was assessed using the common terminology
criteria for adverse events (version 3.0) of the National
Cancer Institute. Administration of hematopoietic growth
factors was at the discretion of the treating physician in
accordance with the American Society of Clinical Oncolo-
gists guidelines. Dose reductions for gemcitabine (1200
mg/m2 and 900 mg/m2), carboplatin (AUC4 and AUC3)
or pemetrexed (400 mg/m2 and 300 mg/m2) were based on
the worst grade of toxicity observed in the previous cycle and
on day 1 blood counts of each cycle. Dose reductions were
made if the absolute neutrophil count was 1500/L, plate-
lets 100,000/L, or if febrile neutropenia occurred. Non-
hematologic grade 3 or 4 toxicity dose reductions were at
physician discretion. A maximum of two dose reductions
were allowed from the planned treatment and were perma-
nent. The patient was removed from the study if the toxicity
remained unresolved after a 2-week delay.
Bevacizumab was discontinued for grade 2 pulmonary
or CNS hemorrhage, any grade 4 hemorrhage, grade 4 protein-
uria, grade 4 congestive heart failure, fistula development,
thromboemboli, wound dehiscence, or reversible posterior leu-
koencephalopathy. Bevacizumab was held for surgical proce-
dures, other proteinuria, hypertension, other hemorrhage, or
other congestive heart failure for up to 4 weeks, or the bevaci-
zumab was discontinued. Patients could continue with chemo-
therapy if bevacizumab was discontinued.
Definition of Response
All patients were evaluated for response by RECIST v1.0.
The best response was obtained from evaluations recorded from
the start of treatment until the end of study treatment.
Statistical Considerations
This primary end point of this randomized phase II
trial was to evaluate the time to progression (TTP) of each
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cohort independently. This trial was not designed to com-
pare cohorts. TTP was defined as the interval between the
date of treatment initiation and the date of PD. The patient
was considered assessable but classified as a treatment
failure if there was discontinuation of treatment because of
toxicity.
Historically, the median TTP for elderly patients with
advanced NSCLC is 6 to 8 months. Bevacizumab adminis-
tration was hypothesized to improve TTP by 40% (in each
cohort). To detect a 40% prolongation in TTP with 90%
power at a two-sided alpha of 5%, a total of 55 patients per
cohort (110 total) were enrolled. Secondary end points in-
cluded assessments of ORR, toxicity, and overall survival
(OS). OS was measured from the date of study entry until the
date of death and was estimated using the method of Kaplan
and Meier.20 The safety data were summarized based on
treatment received.
RESULTS
Patient Characteristics
One-hundred ten patients were enrolled and random-
ized, 55 per cohort. Baseline patient characteristics were
similar in both cohorts (Table 1). Patients had predominantly
stage IV disease, adenocarcinomas, and median ages of 76
(cohort A) and 77 (cohort B).
Treatment Received
The median number of treatment cycles administered in
cohorts A and B were 2.5 cycles (2.5 months; range, 0.5–11
months) and 6 cycles (4.5 months; range, 0.75–9 months),
respectively. Only three patients (5%) in cohort A started
maintenance bevacizumab therapy (median number of main-
tenance cycles 6; range, 2.3–5.5 months). Forty-nine percent
of patients in cohort B started maintenance bevacizumab
(median number of maintenance cycles 5; range, 1.4–15.4
months). One patient in cohort A and seven patients in cohort
B are still receiving maintenance bevacizumab at the time of
this analysis.
Dose reductions occurred in both cohorts. Eighteen
patients (33%) in cohort A and 23 patients (42%) in cohort B
experienced at least 1 chemotherapy dose reduction. The
most common reasons for gemcitabine/pemetrexed dose re-
ductions were neutropenia and fatigue. The most common
reasons for carboplatin/pemetrexed dose reductions were
neutropenia and thrombocytopenia.
Bevacizumab was held at least once in 28 patients (51%)
in cohort A and in 5 patients (9%) in cohort B. These holds were
primarily because of hospitalizations or toxicities such as infec-
tions, thromboembolic events, proteinuria, and bleeding.
Growth factor support was common in both cohorts.
Granulocyte colony-stimulating factor was administered in
18% and 38% (cohorts A and B, respectively), and erythro-
poietin was administered in 38% and 36% (cohorts A and B,
respectively). Approximately 20% of patients in each cohort
received red blood cell transfusions.
Efficacy
Best responses for all patients are summarized by cohort
(Table 2). All patients were included in the efficacy analyses.
One patient had a complete response (2%) and 18 patients had
a partial response (33%) for an ORR of 35% (95% confidence
interval [CI], 23–49%) in cohort A. Eighteen patients (33%) had
stable disease, whereas seven patients had PD (13%). Nineteen
patients in cohort B had a partial response (35%; 95% CI,
23–49%) in cohort B. Twenty-five patients had stable disease
(45%) and six patients had PD (11%).
Eleven patients in cohort A and five patients in cohort
B were not evaluable for response. The reasons included the
following: (cohort A) toxicities (rash, cytopenias, diarrhea,
and fatigue; 1 patient each), physician discretion (5), infec-
tion (1), and patient decision (1); (cohort B) patient decision
(2), hyponatremia (1), and myocardial infarction and cardio-
pulmonary arrest (both unrelated; 1 patient each).
Thirty-six percent of patients in cohort A are alive with
a median follow-up of 11.4 months. Fifty-eight percent of
patients in cohort B are alive with a median follow-up of 13.8
months. The median TTP in cohort A was 4.7 months (95%
CI, 3.8–5.8 months), and 10.2 months (95% CI, 6.3–12.7
months) in cohort B (Figure 1). The median overall survivals
for cohorts A and B were 7.5 months (95% CI, 5.6–11.3
months) and 14.8 months (95% CI, 10.25–upper limit not
TABLE 1. Patient Characteristics
Characteristic
No. of Patients (%)
Cohort A, (n  55) Cohort B, (n  55)
Median age, range (yr) 76 (70–89) 77 (70–88)
Sex, n (%)
Male 29 (53) 26 (47)
Female 26 (47) 29 (53)
ECOG performance
status, n (%)
0 25 (45) 21 (38)
1 30 (55) 34 (62)
Race, n (%)
Caucasian 53 (96) 52 (95)
African-American 2 (4) 3 (5)
Stage, n (%)
IIIB 5 (9) 8 (14)
IV 50 (91) 47 (86)
Histology, n (%)
Adenocarcinoma 43 (78) 44 (80)
Large cell 2 (4) 4 (7)
Not otherwise specified 10 (18) 7 (13)
TABLE 2. Best Response Rates
Cohort A, (n  55) Cohort B, (n  55)
Response, n (%)
Complete response 1 (2) 0
Partial response* 18 (33) 19 (35)
Stable disease 18 (33) 25 (45)
Progressive disease 7 (13) 6 (11)
Not evaluable 11 (20) 5 (9)
*Nine confirmed (A) and 12 confirmed (B).
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reached), respectively (Figure 2). One-year survivals for
cohorts A and B were 33% and 59%, respectively.
Treatment-Related Toxicity
Treatment-related toxicities for all patients are summa-
rized in Tables 3 and 4. Thirteen patients on cohort A (23%)
were removed from study treatment because of toxicities such
as severe infection, hematologic toxicity, and fatigue. Of the
patients in cohort B, only five (9%) were removed from study
treatment because of toxicity, ranging from thromboembolic
episodes, proteinuria, and hematologic toxicity. Randomiza-
tion to treatment arms and subsequent reasons for treatment
discontinuation are illustrated in Figure 3.
The most frequent grade 3/4 toxicity associated with
both treatment regimens was hematologic. Hematologic toxici-
ties included the following: neutropenia (cohort A, 51%/B,
45%), leukopenia (A, 40%/B, 27%), anemia (A, 22%/B, 7%),
and thrombocytopenia (A, 11%/B, 31%). Severe and life-threat-
ening febrile neutropenia was limited to four patients in cohort A
(7%). Twelve patients in cohort A (22%) and 11 patients (20%)
in cohort B received packed red blood cell transfusions with a
median of two transfusions administered per cohort. Platelet
transfusions were infrequent, with no patients in cohort A and
only three patients (5%) in cohort B undergoing transfusions.
Fatigue (36%), dyspnea (20%), and infection (25%,
including pneumonia, cellulitis, and sepsis) were notable
FIGURE 1. Time to progression (TTP).
FIGURE 2. Overall survival probability.
TABLE 3. Cohort A—Gemcitabine/Pemetrexed Treatment-
Related Toxicity* (n  55)
No. of Patients (%)
Grade 3 Grade 4 Grade 5 Total
Hematologic
Anemia 11 (20) 1 (2) 0 12 (22)
Leukopenia 17 (31) 5 (9) 0 22 (40)
Neutropenia 13 (24) 15 (27) 0 28 (51)
Febrile neutropenia 3 (5) 1 (2) 0 4 (7)
Thrombocytopenia 5 (9) 1 (2) 0 6 (11)
Nonhematologic
Anorexia 3 (5) 0 0 3 (5)
Cardiac arrhythmia 2 (4) 1 (2) 0 3 (5)
Dehydration 4 (7) 0 4 (7)
Dyspnea 10 (18) 0 1 (2) 11 (20)
Fatigue 19 (35) 1 (2) 0 20 (36)
Hypertension 1 (2) 0 0 1 (2)
Hyponatremia 0 4 (7) 0 4 (7)
Infection 12 (22) 0 2 (4) 14 (25)
Muscle pain 4 (7) 0 0 4 (7)
Proteinuria 1 (2) 0 0 1 (2)
Respiratory failure 1 (2) 1 (2) 1 (2) 3 (5)
Thrombosis/embolism 2 (4) 2 (4) 0 4 (7)
*In greater than 5% of total patients.
TABLE 4. Cohort B—Carboplatin/Pemetrexed Treatment-
Related Toxicity* (n  55)
No. of Patients (%)
Grade 3 Grade 4 Grade 5 Total
Hematologic
Anemia 4 (7) 0 0 4 (7)
Leukopenia 14 (25) 1 (2) 0 15 (27)
Neutropenia 19 (35) 6 (11) 0 25 (45)
Febrile neutropenia 0 0 0 0
Thrombocytopenia 12 (22) 5 (9) 0 17 (31)
Nonhematologic
Anorexia 0 0 0 0
Cardiac arrhythmia 0 0 0 0
Dehydration 4 (7) 0 0 4 (7)
Dyspnea 5 (9) 1 (2) 0 6 (11)
Fatigue 10 (18) 0 0 10 (18)
Hypertension 3 (5) 1 (2) 0 4 (7)
Hyponatremia 0 1 (2) 0 1 (2)
Infection 4 (7) 0 0 4 (7)
Myalgia 6 (11) 0 0 6 (11)
Proteinuria 2 (4) 1 (2) 0 3 (5)
Respiratory failure 0 0 1 (2) 1 (2)
Thrombosis/embolism 3 (5) 1 (2) 0 4 (7)
*In 5% of total patients.
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severe nonhematologic toxicities in cohort A. The significant
severe nonhematologic toxicities in cohort B were dyspnea
(11%), fatigue (18%), and myalgias (11%). There were 42
hospitalizations in cohort A and 25 hospitalizations in cohort
B. Eight deaths on study in cohort A were noted within the
safety reporting window, three of these were possibly related
to study treatment (sepsis, thrombocytopenia, and myocardial
infarction). Six deaths on study were noted in cohort B. Of
these, two (4%) were possibly related to treatment (sepsis and
pulmonary hemorrhage).
DISCUSSION
Elderly patients represent a large and growing proportion
of the NSCLC population but are still frequently undertreated
and underrepresented in clinical trials.1,3,21–23 Coexisting medi-
cal conditions, polypharmacy, and poor performance status
are common barriers to trial enrollment and treatment.24
Physician and family perceptions are important barriers in
older patients as well.6,25 Therapies used routinely in younger
patients are often viewed as more toxic and relatively inef-
fective in elderly patients with life-threatening disease. Nev-
ertheless, national guidelines discourage the use of age as a
factor in treatment selection as mounting evidence from
randomized trials supports the role of chemotherapy in older
patients with advanced NSCLC.26–31
This trial was designed to assess two pemetrexed/
bevacizumab-based first-line NSCLC regimens. The favor-
able therapeutic index of pemetrexed made it an ideal agent
to use in combination with bevacizumab, an agent with broad
activity in multiple tumor settings, but uncommon severe
toxicity. Biweekly pemetrexed and gemcitabine had been
previously studied at our center and by others and found to be
generally well tolerated with modest activity.14–16 Similarly,
carboplatin and pemetrexed has proven to be safe and com-
FIGURE 3. CONSORT diagram.
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parable with other platinum doublets in the first-line setting.9
More recently, carboplatin, pemetrexed, and bevacizumab
has emerged as a promising active regimen and is currently in
phase III testing.30,32 Our trial was designed to assess pem-
etrexed/gemcitabine/bevacizumab and pemetrexed/carbopla-
tin/bevacizumab for preliminary efficacy and safety in elderly
patients in the first-line setting.
Patient age ranged from 70 to 89 years and most had a
PS of 1. Overall, each regimen was found to be well tolerated,
although cytopenias and fatigue were notable in each cohort,
and potential treatment-related deaths were seen in 5% and
4% of patients in cohorts A and B, respectively. Serious
infection was relatively common in the gemcitabine group
(25%), but only observed in 7% with carboplatin. Among all
patients, two patients (2%) may have died because of treat-
ment-related infection. Serious bleeding or thromboembolic
events were rare.
In terms of efficacy, each regimen was associated with
response and disease-control rates expected of modern dou-
blet regimens in relatively younger patients treated in the
first-line setting. The 35% response rates for each cohort
compare favorably with the 35% response rate seen in the
pivotal randomized trial with carboplatin, paclitaxel, and
bevacizumab where 57% of the participants were aged 64
years or younger.17 Nevertheless, such comparisons should
also include the higher 55% rate seen in the Patel et al.30 trial
with carboplatin, pemetrexed, and bevacizumab.
A notable finding in our trial was the prolonged TTP
(10.2 months) and overall survival (14.8 months) in the
carboplatin cohort. These rates are among the highest re-
ported from our center in the first-line NSCLC setting in any
population. In contrast, patients in the gemcitabine cohort had
an overall survival of 7.5 months, more consistent with
previous results in this patient group.
This trial has several limitations. The size of the patient
cohorts in this randomized phase II study results in wide confi-
dence limits around the efficacy end points and prevents defin-
itive comparison of these two regimens. All patients in this trial
were considered to be candidates for bevacizumab treatment and
therefore may not truly reflect the overall population of elderly
patients seen in practice. The different assessment intervals for
the two treatment cohorts (8 weeks versus 9 weeks) may also
have affected the progression free survival determinations.
In summary, this trial demonstrates that pemetrexed/
bevacizumab-based regimens are active and tolerable as
first-line therapies for elderly patients with advanced
NSCLC. The carboplatin/pemetrexed/bevacizumab regi-
men in particular was associated with long TTP and overall
survival. This regimen is the experimental arm of an
ongoing large randomized trial versus carboplatin/pacli-
taxel/bevacizumab in the first-line setting not limited to
elderly patients.32 Hopefully, enough elderly patients will
be included to permit a subset analysis for safety and
efficacy. These trials offer potential important opportunities
to advance care for our elderly patients.
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